Shares in Coiled Therapeutics (AIM:COIL) jumped 25% to 11p after it flagged the start to trading on the OTCQB Venture Market in the United States under the ticker COTXF.
The cross-listing allows US investors to trade the company's shares in dollars during US market hours through brokers including Fidelity, Charles Schwab and Interactive Brokers, to improve liquidity and broaden the shareholder base.
The oncology R&D specialist's shares will continue to trade on AIM under the existing COIL ticker.
As a foreign private issuer, Coiled has qualified for the OTCQB under an exemption from full SEC reporting, meaning the listing carries minimal additional costs and no new reporting obligations beyond making home market disclosures available in English.
Chief executive Sridhar Vempati said the US listing complemented the AIM admission at "an exciting time" for the company, pointing to recent clinical data from its ongoing trial showing an 80% clinical benefit rate with durable responses in heavily pre-treated patients.
Dose escalation is on track for completion in the first half of 2026, with multiple data catalysts expected through the year.
Vempati said he believed 2026 would be "a transformational year" for the business.